Home›Trial›NCT07229157
🔬NCT07229157Phase 1ACTIVE NOT RECRUITING

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Study Summary

The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.

Conditions
OverweightObesity
Interventions / Drugs
Maridebart CafraglutideMoxifloxacinPlacebo for Maridebart CafraglutidePlacebo for Moxifloxacin
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment81 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.157741+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.